Market Cap 13.68M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 104,200
Avg Vol 163,678
Day's Range N/A - N/A
Shares Out 15.98M
Stochastic %K 22%
Beta -1.73
Analysts Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Alfaseeka
Alfaseeka Aug. 4 at 11:45 AM
$TPST I gave up on this, what’s the deal for the 2nd vote?
2 · Reply
Michl2000
Michl2000 Aug. 4 at 3:58 AM
$TPST 💩💩💩🥳
0 · Reply
lousjamsession
lousjamsession Aug. 3 at 7:59 PM
0 · Reply
zambono
zambono Aug. 3 at 7:48 PM
$TPST doubled down, don’t read much into it. Since my average was over $6, not much to loose.
0 · Reply
Michl2000
Michl2000 Aug. 3 at 3:34 PM
$TPST 💩💩💩
0 · Reply
lgb2
lgb2 Aug. 2 at 11:19 PM
$TPST 💩🤮
0 · Reply
joeyknowie
joeyknowie Aug. 2 at 8:44 PM
$TPST granted this ticker may continue to fall flat on its face. 3 reasons for positive thoughts though: 1) good science (hasn’t changed and maybe has gotten stronger since factor deal); 2) Chinese connections with big money backing; 3) Heavy insider ownership with company trajectory driven by CEO owner insider with good track record and stellar credentials. It could definitely still fail but there are some reasons to think it may be the small cap bio exception. Time will tell and probably sooner than later as in this year or early next given stock price, cash position, and factor “cash runway” commitment to mid-2027.
0 · Reply
Onedaytolive
Onedaytolive Aug. 1 at 12:23 AM
$TPST Since we’re in a do-or-die situation, should we vote in favor to entrust everything to the Angel CEO? The fact that they’re urging us to hold a second vote suggests that the failure of the first vote was calculated all along and is meant to send us a message.
2 · Reply
lousjamsession
lousjamsession Jul. 31 at 6:11 PM
0 · Reply
Michl2000
Michl2000 Jul. 31 at 3:07 PM
0 · Reply
Latest News on TPST
Tempest Therapeutics Proxy statement: Proxy filing

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Proxy statement: Proxy filing

Jul 17, 2026, 8:00 AM EDT - 18 days ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Slides: Corporate presentation

Jul 15, 2026, 8:00 AM EDT - 20 days ago

Tempest Therapeutics Slides: Corporate presentation


Tempest Therapeutics Proxy statement: Proxy filing

Jul 7, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

Tempest Therapeutics Earnings release: Q1 2026


Tempest Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

Tempest Therapeutics Quarterly report: Q1 2026


Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting


Tempest Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Therapeutics Slides: Corporate presentation


Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 4 months ago

Tempest Therapeutics Annual report: Q4 2025


Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 4 months ago

Tempest Therapeutics Earnings release: Q4 2025


Tempest Therapeutics Registration statement: Registration filing

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Tempest Therapeutics Registration statement: Registration filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 8 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 19, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

Tempest Therapeutics Quarterly report: Q3 2025


Tempest Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

Tempest Therapeutics Earnings release: Q3 2025


Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 9 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year


Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q2 2025


Tempest Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q2 2025


Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat


Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025


Tempest Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025


Tempest Therapeutics Slides: Corporate Presentation

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation


Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024


Tempest Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024


Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024


Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024


Tempest Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024


Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update


Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update


Tempest Therapeutics Press release: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update


Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024


Tempest Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023


Tempest Therapeutics Annual report: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023


Tempest Therapeutics Slides: Corporate Presentation

Nov 20, 2023, 5:00 AM EST - 2 years ago

Tempest Therapeutics Slides: Corporate Presentation


Alfaseeka
Alfaseeka Aug. 4 at 11:45 AM
$TPST I gave up on this, what’s the deal for the 2nd vote?
2 · Reply
Michl2000
Michl2000 Aug. 4 at 3:58 AM
$TPST 💩💩💩🥳
0 · Reply
lousjamsession
lousjamsession Aug. 3 at 7:59 PM
0 · Reply
zambono
zambono Aug. 3 at 7:48 PM
$TPST doubled down, don’t read much into it. Since my average was over $6, not much to loose.
0 · Reply
Michl2000
Michl2000 Aug. 3 at 3:34 PM
$TPST 💩💩💩
0 · Reply
lgb2
lgb2 Aug. 2 at 11:19 PM
$TPST 💩🤮
0 · Reply
joeyknowie
joeyknowie Aug. 2 at 8:44 PM
$TPST granted this ticker may continue to fall flat on its face. 3 reasons for positive thoughts though: 1) good science (hasn’t changed and maybe has gotten stronger since factor deal); 2) Chinese connections with big money backing; 3) Heavy insider ownership with company trajectory driven by CEO owner insider with good track record and stellar credentials. It could definitely still fail but there are some reasons to think it may be the small cap bio exception. Time will tell and probably sooner than later as in this year or early next given stock price, cash position, and factor “cash runway” commitment to mid-2027.
0 · Reply
Onedaytolive
Onedaytolive Aug. 1 at 12:23 AM
$TPST Since we’re in a do-or-die situation, should we vote in favor to entrust everything to the Angel CEO? The fact that they’re urging us to hold a second vote suggests that the failure of the first vote was calculated all along and is meant to send us a message.
2 · Reply
lousjamsession
lousjamsession Jul. 31 at 6:11 PM
0 · Reply
Michl2000
Michl2000 Jul. 31 at 3:07 PM
0 · Reply
lgb2
lgb2 Jul. 31 at 12:42 AM
$TPST just like the poison pill
0 · Reply
lgb2
lgb2 Jul. 31 at 12:41 AM
$TPST dead zone
1 · Reply
lgb2
lgb2 Jul. 31 at 12:41 AM
$TPST in the past few years
0 · Reply
yyrrrp
yyrrrp Jul. 30 at 11:29 PM
$TPST ok not much has changed here. Just checking in. 💩
0 · Reply
Michl2000
Michl2000 Jul. 30 at 7:23 PM
$TPST 💩
0 · Reply
Michl2000
Michl2000 Jul. 30 at 7:23 PM
$TPST 💩💩
0 · Reply
Michl2000
Michl2000 Jul. 30 at 5:40 PM
$TPST 💩💩💩
0 · Reply
lousjamsession
lousjamsession Jul. 30 at 2:25 PM
$TPST is hovering right around $0.88, sitting comfortably close to its main support zone near $0.85. If buyers step up and defend this level, it gives the stock a great opportunity to build a solid base and bounce back. However, if it slips under $0.85, the safety net gets pretty thin, which could temporarily slide the price down toward $0.50 before finding strong new support.
1 · Reply
joeyknowie
joeyknowie Jul. 30 at 12:30 PM
$TPST would they dilute more at this share price? Absent a sale or licensing deal for the legacy assets they may have no choice.
0 · Reply
Xamayca
Xamayca Jul. 30 at 12:45 AM
$TPST Based on what formula do we calculate a cash runway to mid -2027? Surely the diminution of the share price since the factor deal requires an adjustment to that estimate?
1 · Reply
claybridge
claybridge Jul. 29 at 3:08 PM
0 · Reply
Michl2000
Michl2000 Jul. 29 at 2:51 PM
$TPST These idiots fail in everything. Ridiculous!
0 · Reply